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Introduction: The management of metastatic breast cancer needs improvement. As clinical evaluation is not very
accurate in determining the progression of disease, the analysis of circulating tumor DNA (ctDNA) has evolved to
a promising noninvasive marker of disease evolution. Indeed, ctDNA was reported to represent a highly sensitive
biomarker of metastatic cancer disease directly reflecting tumor burden and dynamics. However, at present little
is known about the dynamic range of ctDNA in patients with metastatic breast cancer.
Methods: In this study, 74 plasma DNA samples from 58 patients with metastasized breast cancer were analyzed
with a microfluidic device to determine the plasma DNA size distribution and copy number changes in the plasma
were identified by whole-genome sequencing (plasma-Seq). Furthermore, in an index patient we conducted
whole-genome, exome, or targeted deep sequencing of the primary tumor, metastases, and circulating tumor cells
(CTCs). Deep sequencing was done to accurately determine the allele fraction (AFs) of mutated DNA fragments.
Results: Although all patients had metastatic disease, plasma analyses demonstrated highly variable AFs of
mutant fragments. We analyzed an index patient with more than 100,000 CTCs in detail. We first conducted
whole-genome, exome, or targeted deep sequencing of four different regions from the primary tumor and three
metastatic lymph node regions, which enabled us to establish the phylogenetic relationships of these lesions,
which were consistent with a genetically homogeneous cancer. Subsequent analyses of 551 CTCs confirmed the
genetically homogeneous cancer in three serial blood analyses. However, the AFs of ctDNA were only 2% to 3%
in each analysis, neither reflecting the tumor burden nor the dynamics of this progressive disease. These results
together with high-resolution plasma DNA fragment sizing suggested that differences in phagocytosis and DNA
degradation mechanisms likely explain the variable occurrence of mutated DNA fragments in the blood of
patients with cancer.
Conclusions: The dynamic range of ctDNA varies substantially in patients with metastatic breast cancer. This has
important implications for the use of ctDNA as a predictive and prognostic biomarker.Introduction
Measuring treatment response in patients with metastatic
breast cancer is usually done by serial clinical evaluation
of symptoms and estimates of tumor burden. However,
serial radiographic imaging is expensive, often inconclu-
sive, and may fail in detecting changes in tumor burden.
Cancer antigen 15-3 (CA 15-3) has reasonable sensitivity,
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unless otherwise stated.response or progression [1]. Hence, ‘liquid biopsies’, that is,
analyses of circulating tumor cells (CTCs) or plasma
DNA, have recently acquired considerable interest [2-4].
Indeed, the enumeration of CTCs has evolved to a prom-
ising biomarker [5]. The CellSearch System (Janssen Diag-
nostics, LLC, New Brunswick, NJ, USA) has been cleared
by the Food and Drug Administration, as increased CTC
numbers, that is five or more cells per 7.5 ml of blood, in
patients with metastatic breast cancer have been associ-
ated with a worse prognosis [6,7]. As a substantial fraction
of patients with metastatic cancer have unexpectedly lowl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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assays are under development [3].
Furthermore, tumor cells release DNA fragments into
the circulation, termed circulating tumor DNA (ctDNA),
which can be found in the cell-free fraction of blood
together with DNA fragments from normal cells,
which is commonly referred to as cell-free DNA (cfDNA)
[3,8,9]. Tumor-specific sequence alterations in plasma
were used to quantify tumor burden [10-13] or for
genome-wide analyses of tumor genomes [14-19]. Mul-
tiple studies have suggested that ctDNA can be used to
monitor tumor dynamics [10-14,16,17,20-23]. For ex-
ample, a recent study has reported that in women with
breast cancer the ctDNA levels showed a greater dynamic
range, and greater correlation with changes in tumor
burden than CA 15-3 or CTCs [13]. For these reasons, it
was even proposed that the serial analysis of cancer ge-
nomes in plasma constitutes a new paradigm for the study
of clonal evolution in human cancers [17].
We studied ctDNA in 58 women with metastasized
breast cancer. We exemplify our observations using an
index case with extensive metastases to the bones and
liver and excessive CTC numbers (n = approximately
50,000 to >100,000) in serial analyses, which we examined
with whole-genome, exome and targeted deep sequencing.
Methods
Plasma DNA extraction and sizing
Plasma DNA was extracted as previously described [15].
The size distribution of plasma DNA fragments was
evaluated on an Agilent 2100 Bioanalyzer using the
DNA series Agilent High Sensitivity DNA kit (Agilent
Technologies, Santa Clara, CA, USA).
Collection and procession of material from the index
patient
Material was obtained by microdissection from the four lar-
gest tumor foci, designated as tumor A (diameter: 6 mm),
B (12 mm), C (8 mm), and D (11 mm), and from five met-
astatically involved lymph nodes, designated as LN15 (one
lymph node metastasis of 1 cm diameter), LN17 (three
neighboring lymph node metastases of 3, 6 and 8 cm,
respectively, in diameter, embedded together in one block
and harvested together for DNA extraction), and LNA (a
sentinel node with 1.2 cm metastasis) (Figure 1). From all
lesions a tumor DNA content of at least 70% was ac-
quired. In addition, we obtained saliva in order to get
tumor-free, germline DNA. We collected blood for
CTC and ctDNA analysis at three different time points
(Figure 1). From these blood samples we prepared plasma
DNA and enumerated CTCs using the FDA-cleared
CellSearch system (Janssen Diagnostics, LLC). For further
analyses, CTCs were isolated from the CellSearch system
as previously described [24]. In addition, we isolated CTCsafter Oncoquick density gradient centrifugation and
staining with EpCAM and CD45 using the CellCelector
(ALS, Jena, Germany), based on their staining pattern, that
is EpCAM+/CD45- cells. DNA from CTCs was subjected
to whole-genome amplification (WGA), that is lysis
with protease followed by Phi29 amplification as de-
scribed [24].
All blood samples were collected before the adminis-
tration of each treatment cycle. The study was approved
by the ethics committee of the Medical University of
Graz (approval number 21-227 ex 09/10) and conducted
according to the Declaration of Helsinki, written informed
consent was obtained from all patients. The index patient
has provided informed consent to publish the information
contained in this manuscript.
Isolation of CTCs using the CellSearch or the CellCelector
systems
Blood samples (7.5 ml each) were collected into CellSave
tubes (Veridex, Raritan, NJ, USA). We have described
capturing of CTCs with the CellSearch system before
[24,25]. In brief, CTCs were enriched and enumerated
employing the Epithelial Cell Kit (Veridex). Subsequently,
we captured CTCs by anti-epithelial cell adhesion mol-
ecule (EpCAM)-antibody-bearing ferrofluid. We identified
CTCs based on cytokeratin-positivity and negativity for
the leukocyte common antigen CD45. Furthermore, cells
were stained with 4′,6-diamidino-2-phenylindole (DAPI)
to evaluate the integrity of the nucleus.
For the CellCelector system (ALS) we first performed
density gradient centrifugation with Oncoquick™ (Greiner
Bio-One, Kremsmunster, Austria) and then cells were
stained with anti-EpCAM and anti-CD 45 antibody. Using
the CellCelector, only EpCAM-positive and CD45-
negative cells were isolated with a 50 μm capillary at
an amount of 0.8 μl phosphate-buffered saline and trans-
ferred into the cap of a 200 μl tube, containing 7 μl of
nuclease-free water. After centrifugation cells were frozen
for at least one hour at −20°C prior to WGA.
Whole-genome amplification for CTC analysis
The DNA of single or few CTCs had to be subjected to
WGA for further analysis. The WGA protocol was de-
scribed in detail in our previous publications [24,26-28].
Establishment of copy number profiles
In order to establish copy number profiles from the
various samples we prepared libraries and subjected
them to whole-genome sequencing at a shallow sequen-
cing depth (0.1x) as previously described [18,19]. For CTC
analyses, we used - after WGA - either whole-genome
sequencing or array-CGH to determine copy number
changes. The array-CGH protocols were published previ-
ously [24,26-28].
Figure 1 Timeline of the clinical course of the index patient and results obtained from the analyzed primary tumor and metastatic
lesions. (a) The timeline starts with a sketch illustrating the localization of the lesions we subjected to our analyses, that is primary tumor lesions
A, B, C, and D and lymph node metastases LN15, LN17, and LNA from the right axilla as observed at the time of diagnosis. In the timeline, dates
when clinical progress was noted are indicated with a blue bar and the time points of blood collections (B) by a red bar (for details see text).
(b) Copy number profiles obtained by whole-genome sequencing from tumor C and lymph node metastasis LN17. The X-axis shows the chromosome,
the Y-axis indicates log2-ratios. (c) Mutation frequencies of genes PCDH20, OR4X1, ALK, DNPEP, SH3TC2, DDR2, MLL3, and PIK3CA as established by targeted
deep sequencing in the tumor lesions and lymph node metastases. (d) The clonal evolutionary relationships of the analyzed lesions based on the
frequency of single nucleotide variants (SNVs) as shown in (c). The arrow indicates an increase in the frequency of the respective SNV, the ‘+’ a newly
occurred SNV. The three lymph node metastases are indicated together in the circle labeled ‘LN’.
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For all primary tumor lesions (A, B, C, and D), for
lymph node metastases (LN15, LN17, and LNA), and for
the constitutional DNA from saliva we sequenced the
complete coding regions of the genome, that is conduc-
ted exome sequencing at a sequencing depth of approxi-
mately 50x. Prior to exome enrichment 300 to 400 bps
libraries were prepared using the TruSeq DNA Sample
Prep Kit (Illumina, San Diego, CA, USA). Exome enrich-
ment was performed using the TruSeq Exome Enrichment
Kit (Illumina) according to the manufacturer’s instruc-
tions. Briefly, libraries were pooled equimolarily and hybri-
dized in two reactions to the exome capture probes at
58°C for 16 to 20 h. Streptavidin beads were used to pull
down the complex of captured oligos and genomic DNA
fragments, whereas unbound fragments were removed by
a first wash. To further enrich the target regions, a secondhybridization was performed followed by another pull
down with streptavidin beads. Finally, the enriched frag-
ment pools were amplified for 15 cycles of PCR. Enriched
libraries were quality checked on an Agilent 7500 DNA
kit (Agilent Technologies) and quantified using qPCR.
The enriched library pools were then sequenced across
two lanes of a HiSeq 2000 (Illumina), where a mean of 49
million reads for the formalin-fixed paraffin-embedded
samples and 153 million reads for the constitutional DNA
was obtained.
Bioinformatics
Sequences were aligned to the human genome (hg19) using
Burrows-Wheeler Algorithm (BWA; MEM-algorithm,
version 0.7.4-r385) [29] with default alignment parame-
ters. Somatic single nucleotide polymorphisms (SNPs)
were called using the MuTect algorithm [30]. In addition,
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of the constitutional DNA by using the UnifiedGenotyper
of the Genome Analysis Toolkit (version 1.6-13) [31].
In order to identify phylogenetic relationships between
copy number profiles of tumors, lymph nodes, and CTCs,
we calculated the distance matrix (from Manhattan dis-
tances) based on the copy number status of the 50,000
bins from the whole-genome sequencing approach and
subsequently created a dendrogram. To summarize copy
number aberrations of unbalanced plasma samples, we
subjected our plasma-Seq data to the Genomic Recurrent
Event ViEwer (GREVE) algorithm [32]. Details on settings
of the software parameters are available on request.
Variant prioritizing
We utilized exome sequencing from DNA obtained from
saliva (germline DNA), tumor lesions A, C, D (the DNA
quality from tumor B was not sufficient for exome se-
quencing) and for the metastases LN15, LN17, and LNA
to search for single nucleotide variants (SNVs) inform-
ative for establishing a phylogenetic relationship.
After applying the aforementioned filter and restric-
tion of analysis to exons with their adjacent 2 bps on
each side, exome sequencing identified 21,741 SNVs in
the germline DNA, 20,749 of which were in the Single
Nucleotide Polymorphism Database (dbSNP132) and
992 were novel. We then used the exome data from the
tumor lesions to filter for somatic SNVs and found
somatic SNV numbers between 716 (tumor C) and
1,589 (LN15). In order to minimize our dataset and
therefore make it feasible for validation of the identified
variants with an independent method, we first focused
on mutations in known driver genes that are listed in
the Catalogue of Somatic Mutations (COSMIC; [33]),
thereby reducing the number of SNVs to <20/sample.
Subsequently, we filtered for identical SNVs present in
more than one sample and confirmed those SNVs by
targeted amplicon sequencing. These efforts resulted
in the identification of SNVs in eight genes (that is
PCDH20, OR4X1, ALK, DNPEP, SH3TC2, DDR2, MLL3,
and PIK3CA) (Table S1 in Additional file 1), which
appeared to be informative for addressing the clonal rela-
tionship of the various lesions. We then used targeted
deep sequencing to accurately establish the allele fre-
quency of these SNVs in each sample.
Targeted deep sequencing
We used somatic mutations as established in the previ-
ous steps to conduct targeted deep sequencing of tumor
samples, CTC amplification products, and plasma DNA.
For the latter DNA samples deep sequencing of PCR
products allowed us to determine the allele fraction (AF)
of the mutant alleles in the sample analyzed. Targeted
deep sequencing was performed on the Illumina MiSeq™System. In brief, primers were designed for all mutations
as listed in Table S1 in Additional file 1 and Illumina-
specific adapters were attached to the 5′ ends in round
of PCR. PCR was performed using the FastStart High
Fidelity PCR System (Roche, Basel, Switzerland) accord-
ing to the manufacturers’ recommendation. The PCR
products were purified using the Agencourt AMPure
kit (Beckman Coulter, Brea, CA, USA) as described in
the manufacturer’s protocol and purified products were
quantified using a Bioanalyzer High Sensitivity Chip
(Agilent Technologies). The PCR products were pooled
equimolarly and sequenced on the Illumina MiSeq™
System in a 2 × 150 bps run. Obtained sequence reads
were base called, filtered by quality metrics, and aligned to
the human reference sequence. We set a cutoff of 1% mu-
tated fragments for reliable detection of mutant alleles in
plasma DNA.
Accession numbers
All sequencing raw data were deposited at the European
Genome-phenome Archive (EGA, [34]), which is hos-
ted by the EBI, under the study accession number
EGAS00001000625.
Results and discussion
Our aim was to investigate the significance of mutant
AFs in a series of plasma samples from patients with
metastatic breast cancer. As there is an ongoing discus-
sion whether ctDNA and CTCs are rivals or partners in
cancer care [9], we first describe our comprehensive ana-
lyses of an index patient with more than 100,000 CTCs
in serial analyses and provide in parallel detailed single
CTC and ctDNA analyses. In order to explore to what
extent the ctDNA findings from this index patient are
generalizable, we then extended our analyses by collecting
mutant AFs in a further 71 plasma samples from 57 pa-
tients with metastasized breast cancer.
History of the index case with more than 100,000 CTCs
The index case was a 40-year-old premenopausal woman
diagnosed with a right-sided multifocal (seven lesions),
invasive lobular breast cancer. The location of four
of the seven foci which we analyzed is illustrated in
Figure 1a. They were estrogen (ER) and progesterone
(PR) receptor positive (Allred score of 8), without
Her2/neu overexpression and amplification and a low
Ki-67 labeling index of 5% to10%. After surgery, tumor
stage was pT-1c (7), G-2, pN-3a (14/20). After adjuvant
cytotoxic, epirubicin and cyclophosphamide chemother-
apy she received anti-hormonal therapy with tamoxifen.
There was no evidence of disease for two years and five
months. However, 29 months after initial diagnosis,
bone metastases and a thrombocytopenia (59,000/mm3)
were noted (Figure 1a). Chemotherapeutic options were
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only treatment during our study period consisted of vari-
ous endocrine regimens (for more details see Additional
file 2). At month 31 of follow-up, several liver metastases
were noted and we obtained our first and second blood
samples about one and two weeks later, respectively
(Figure 1a). Both blood samples yielded the exceptional
number of more than 100,000 CTCs with the CellSearch
system. At month 32 an increase of the liver metastases
was noted and furthermore ascites were newly diagnosed.
The physical condition of the patient (Karnofsky 60) wors-
ened significantly over time and about one month later,
we obtained the third blood sample (Figure 1a), which
revealed a CTC number of approximately 50,000. White
blood cell counts were with 9.02 G/l, 5.7 G/l, and 8.95 G/l
at the first, second and third blood collections, respec-
tively, within the normal range, no progenitor cells were
observed. Further clinical signs of subileus were noted and
the patient died about nine weeks after our last blood
collection.
Primary tumor lesions and lymph nodes were genetically
homogeneous
We first addressed the question whether the spatially
separated foci (the four analyzed lesions were designated
as A to D; Figure 1a) from the primary tumor were clon-
ally related. Copy number analyses performed by whole-
genome sequencing identified marked similarities char-
acterized by common gains and losses in these separated
foci (that is gains of 1q and 8q, and losses of 6q, 8p, distal
11q, and 17p), suggesting a common origin of these
lesions (the copy number profile of tumor C is exemplarily
illustrated in Figure 1b; see Figure S1a in Additional file 3
for all profiles). We next applied whole-genome sequen-
cing to three lymph nodes (LN15, LN17, and LNA), which
again revealed similar copy number changes as the lesions
from the primary tumor (Figure 1b, and Figure S1b in
Additional file 3). Hence, copy number analyses were sug-
gestive of a close clonal relationship between the various
lesions.
To evaluate this further we utilized exome sequencing for
DNA obtained from saliva (germline DNA) and the afore-
mentioned lesions. After variant prioritizing (see Methods),
we focused on SNVs in genes from the COSMIC database
[33] that were present in three or more samples. This
resulted in the identification of SNVs in eight genes (that is
ALK, DNPEP, OR4X1, PCDH20, SH3TC2, DDR2, MLL3,
and PIK3CA) (Table S1 in Additional file 1), which ap-
peared to be informative for addressing the clonal relation-
ship of the various lesions. We then used targeted deep
sequencing to establish the AF of these SNVs accurately in
each sample with the exception of tumor B, for which there
was not enough DNA left. Read counts of mutated and
total reads are listed in Table S1 in Additional file 1.These efforts indeed confirmed the monoclonal origin
of the various tumor lesions, because somatic SNVs in
five genes (that is ALK, DNPEP, OR4X1, PCDH20, and
SH3TC2) were present in all lesions with approximately
the same AF (Figure 1c). The three other genes (that is
DDR2, MLL3, and PIK3CA) allowed us to gain some
insight into the clonal evolutionary relationships of the
analyzed lesions. The SNV in the DDR2 gene in tumor
A had an increased AF (36.4%) as compared to tumors
C (15.3%) or D (16.6%) and, furthermore, tumor A had a
SNV in MLL3, which was not observed in tumors C and
D. This MLL3 SNV was also observed in the three lymph
nodes, each with a higher AF (from 18.9% in LNA to
24.2% in LN15) than in tumor A (14.1%). In addition, the
lymph nodes had a novel SNV in the PIK3CA gene, which
had not been present in tumors A, C, or D. This SNV was
the N345K mutant, which was previously reported to
change the inactive cytosolic confirmation of PIK3CA to
an activated form on membranes [35]. Together, these
genetic characteristics suggested that tumors C and D
were common ancestors to the other lesions, tumor A
had descended from tumor C and/or D, and the three
lymph nodes had descended from tumor A (Figure 1d).
CTC analyses revealed high degree of similarities to the
primary tumor and metastases
Between initial diagnosis and our first blood collection
31 months had passed. Hence, an important question was
whether the tumor genome had evolutionarily adapted and
developed novel changes. The CellSearch system (Janssen
Diagnostics, LLC) revealed an extraordinary count of more
than 100,000 CTCs at the first two blood collections and
more than 50,000 CTCs at the third. Hence, these CTCs
provided an extraordinary opportunity to address the
aforementioned questions. In order to subject these CTCs
to our single cell analysis tools [24,27,28,36], we isolated
them employing the CellSearch (Janssen Diagnostics, LLC)
or the CellCelector (ALS) systems. Altogether we success-
fully analyzed 551 CTCs, either as single cells (n = 31) or in
pools with various cell numbers (that is 5x = 6; 10x = 6;
25-50x = 5; 50x = 3; 100x = 1). Indeed, our CTC analyses
revealed at all three time points similar patterns of copy
number changes (that is again gains of 1q and 8q, and
losses of 6q, 8p, distal 11q, and 17p) (an exemplary whole-
genome sequencing profile of a single CTC is illustrated
in Figure 2a; further whole-genome sequencing profiles
are depicted in Figure S1c in Additional file 3 and array-
CGH profiles in Figure S2a-b in Additional file 4). As a
novel change in the CTCs we observed loss of chromo-
some 1p. We generated heat maps to illustrate the high
degree of similarities of copy number changes among all
analyzed tumor samples (Figure 2b).
Furthermore, we used deep sequencing to test the
WGA products of the CTCs for the presence of the
Figure 2 Analyses of circulating tumor cells (CTCs) from the index patient. (a) Whole-genome sequencing profile from a single CTC. (b) Left
panel: heat maps from the copy number changes (red: overrepresentation, blue: underrepresentation) demonstrating the similarities between the
various analyzed samples. Right panel: hierarchical clustering (Manhattan distance, complete agglomeration), the dendrogram illustrates the
clonal relationships.
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SNVs from all eight genes in all CTC WGA products,
especially the MLL3 and PIK3CA SNVs (Table S1 in
Additional file 1), suggesting that the CTCs descended
from the clones forming the lymph node deposits. When
we used the copy number data for hierarchical clustering,
the obtained dendrogram reflected the clonal relationships
as established by the SNV patterns, that is tumors C and
D clustered together with some distance to tumor A,
whereas the lymph node deposits and the CTCs formed
clusters of their own (Figure 2b).
ctDNA had unexpected low allele frequencies
Due to the extensive metastatic and progressive disease,
the presence of similar copy number changes, and iden-
tical mutations in all analyzed tumor deposits, we expec-
ted to detect tumor-associated changes in plasma DNA
with ease, as ctDNA is supposed to reflect tumor burden
[10-13,21,37]. As described previously [15], we first used
a microfluidics-based platform for sizing of plasma DNA
fragments and observed in all three measurements
(P1, P2, and P3) an enrichment of plasma DNA frag-
ments within the range of 85 to 250 bps, but not of DNA
fragments with longer sizes, that is in the range of 250 to
450 bps (Figure 3a). This was unexpected, because we hadpreviously reported that the presence of such longer size
DNA fragments indicates a high frequency of ctDNA in
plasma [15]. Indeed, when we performed whole-genome
sequencing (plasma-Seq) [18,19] we obtained balanced
copy number profiles from all three samples (Figure 3b).
As the fraction of tumor DNA in plasma can modulate
copy number aberrations we then used the aforemen-
tioned eight somatic mutations to determine the mutant
AF with targeted deep sequencing. A mean mutant AF of
3.7% ± 1.6% confirmed the low amount of tumor DNA in
all plasma samples (Table S1 in Additional file 1).
We used the deep-sequencing data to calculate the
number of mutant DNA fragments circulating in the
index patient. By deep sequencing we found for the eight
analyzed mutations on average 6,320, 8,524, and 4,419
mutant fragments in the first, second and third blood
collection, respectively (Table S1 in Additional file 1).
Based on previously published calculations, which as-
sumed that the volume of distribution of DNA at steady
state is similar to that of oligonucleotides in primates
(60 to 70 ml/kg) [37], these mutant molecule numbers
would correspond to 2.3*107, 3.1*107, and 1.6*107, re-
spectively, mutant fragments in total blood (for an ap-
proximate body weight of 60 kg for the index patient) at
the time points of the three blood collections. As the half-
Figure 3 Plasma DNA analyses from the index patient. (a) Sizing of the plasma DNA fragments with a microfluidic device, that is the Agilent
2100 Bioanalyzer. All three plasma samples from the index patient (P1, P2, and P3, which correspond to the first, second, and third blood sample)
demonstrated enrichment of short DNA fragments (size range 85 to 250 bps), whereas longer DNA size fragments (250 to 450 bps) were barely
present. (b) Whole-genome sequencing (plasma-Seq) profiles of the three blood samples.
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the number of mutant molecules should approximately
correspond to the number of tumor cells that released
ctDNA at the time of the blood collections. Based on
these calculations the number of mutated DNA fragments
appears to be high. However, we had previously found
mutant AFs in patients with metastatic colorectal or pros-
tate cancer exceeding 30% [15,18]. Murtaza et al. reported
patients with metastasized breast cancer where plasma
samples had mutant AFs exceeding 50% [17]. Considering
the extensively metastasized disease and the exceptional
number of CTCs, the low mutant AF in the index patient
was unexpected. Our whole-genome, exome, and deep-
sequencing data of primary tumor lesions, metastases, and
altogether 551 CTCs indicated a common origin and pres-
ence of a genetically homogeneous cancer in this patient.
Hence, it is unlikely that tumor heterogeneity or domin-
ance of a clone with different characteristics than those of
the analyzed regions may have obscured our analyses.
Mutant AFs in plasma of patients with metastatic breast
cancer are highly variable
As shown in the index case accurate quantification of
ctDNA, AFs can be achieved by targeted deep sequen-
cing. However, the comprehensive catalogs of publically
available genomic breast cancer data generated by the
Cancer Genome Atlas project revealed that only few
genes are recurrently mutated in breast cancer [39].
Instead of massively parallel sequencing of primary
tumors to identify somatic mutations suitable for AFascertainment an easier approach is plasma-Seq, as it
is independent of pre-knowledge of somatic mutations.
We had previously shown [18,19] that plasma-Seq detects
tumor-specific copy number aberrations in plasma if the
mutant AF exceeds 10%, whereas lower mutant AFs may
appear as balanced profiles as in the index case.
In a further 71 plasma probes derived from 57 patients
with metastasized breast cancer we analyzed the plasma
DNA size distribution and investigated the presence of
copy number alterations. Characteristics of these pa-
tients, that is histological features of the primary and the
localization of the metastases are detailed in Table S2 in
Additional file 5. Two exemplary cases are illustrated in
Figure 4a-b. Patient B60 had only an enrichment of
DNA fragments in the range of approximately 160 bps
(Figure 4a) and showed a balanced profile (Figure 4b),
whereas patient B49 had an enrichment of DNA frag-
ments at approximately 310 bps in addition (Figure 4a)
and multiple copy number changes in the plasma-Seq
analysis (Figure 4b). The presence of such longer DNA
fragments appeared to be indeed a good indicator for an
increased mutant AF fraction. We found copy number
changes in 78.1% (25/32) of plasma samples with a
biphasic (that is enrichment of fragments at approximately
160 bps and approximately 310 bps) plasma DNA size dis-
tribution but in only 7.7% (3/39) with a monophasic (that
is only enrichment of approximately 160 bps fragments)
plasma DNA size distribution (P <0.0001; chi-squared test).
We analyzed the copy number patterns (Figure 4c) and
found that these corresponded to those frequently observed
Figure 4 Exemplary plasma DNA analyses from patients B49 and B60 and plasma DNA copy number patterns from a panel of patients
with metastatic breast cancer. (a) Patient B60 demonstrated an enrichment of plasma DNA fragments at 160 bps whereas B49 had plasma
DNA fragments at about 315 bps in addition. (b) Corresponding plasma-Seq profiles of B60 and B49. (c) Copy number patterns established from
a panel of patients with metastatic breast cancer. Depicted are recurrent aberrations (upper panel gains, lower panel losses), the Y-axis represents
relative abundance of respective aberrations of unbalanced copy number profiles. Data from patients with balanced copy number profiles were
not included. These analyses revealed losses of 1p, 8p, 13q, and 16q, and gains of 1q, 8q, 16p, and 17q.
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16q, and gains of 1q, 8q, 16p, and 17q, demonstrating the
specificity of our approach. We also tested whether the
occurrence of copy number changes was correlated with
any clinical characteristics of the patients or features of
the tumor and found a statistical significant correlation
with the presence of liver metastases (P = 0.002; chi-
square test) but not for any other parameter. Overall, this
suggests that patients with metastatic breast cancer may
have highly variable AFs of mutant DNA in their circu-
lation. This is in line with a recent study, which also
reported that the concentration of ctDNA varied even
among patients with the same tumor type [23].
The observed different patterns of mutant AFs in
the plasma of advanced stage patients, as illustrated
in Figure 4, suggest that the mechanism of ctDNA re-
lease may not be the same in all patients. The lengths ofDNA fragments provide a glimpse into the mechanisms
underlying ctDNA release into the circulation. Macro-
phages engulfing apoptotic or necrotic cells may release
digested DNA into the circulation. As this process in-
volves both neoplastic cells and surrounding stromal and
inflammatory cells, the released DNA is a mixture of wild-
type and mutant sequences. Plasma DNA fragments
within the size range of 85 to 230 bps likely reflect
enzymatic processing and release of DNA from apoptotic
cells, because the length of these fragments corresponds
to the DNA wrapped around a nucleosome (appro-
ximately 142 bps) plus a linker (approximately 20 bps)
[37,41]. Accordingly, the longer DNA fragments likely
represent di- and trinucleosomal DNA. Hence, their pres-
ence suggests that in a subset of patients with cancer
phagocytosis and subsequent release of the digested DNA
into the circulation may be affected. Other contributing
Heidary et al. Breast Cancer Research 2014, 16:421 Page 9 of 10
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saturation of DNA degradation mechanisms due to high
amounts of DNA.
Conclusions
Clinical response evaluation of patients with cancer is
often not accurate. Therefore, the use of ctDNA has
been proposed as a biomarker for monitoring tumor
burden and treatment response. Indeed, several studies
have suggested that ctDNA analysis is an effective indi-
cator of tumor load, allowing more accurate monitoring
of tumor dynamics [10-13,21,37]. In breast cancer, a
recent study has provided evidence that ctDNA levels
had a greater dynamic range and greater correlation with
changes in tumor burden than CA 15-3 or CTCs [13].
However, our study indicates that the biology of CTC
and ctDNA release into the circulation is yet poorly
understood, because we show that CTC numbers and
ctDNA AFs may yield discrepant results. High-resolution
plasma DNA fragment sizing suggested that differences in
phagocytosis and DNA degradation mechanisms may
contribute to variant ctDNA levels. Hence, the future use
of both CTCs and ctDNA as liquid biopsy to monitor
tumor disease will depend on an improved knowledge
about mechanisms of CTC and ctDNA biology in cancer
patients receiving systemic therapy.
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